OSE Immunotherapeutics SA (FRA:6OP)
Germany
· Delayed Price · Currency is EUR 5.05
-0.11 (-2.04%)
At close: Dec 5, 2025
OSE Immunotherapeutics Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 37.45 | -23 | -17.76 | -16.85 | -16.56 | Upgrade
|
| Depreciation & Amortization | 0.95 | 3.53 | 3.54 | 2.66 | 0.73 | Upgrade
|
| Other Amortization | 2.36 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 2.09 | 1.75 | 2.73 | 2.94 | 1.79 | Upgrade
|
| Other Operating Activities | 6.24 | -0.98 | -3.38 | 0.64 | -2.32 | Upgrade
|
| Change in Accounts Receivable | -3.16 | -0.58 | - | - | - | Upgrade
|
| Change in Accounts Payable | -1.57 | 0.76 | - | - | - | Upgrade
|
| Change in Income Taxes | -2.62 | -0.22 | -0.24 | -0.33 | - | Upgrade
|
| Change in Other Net Operating Assets | 6.71 | -1.02 | -3.14 | 1.03 | -3.19 | Upgrade
|
| Operating Cash Flow | 48.44 | -19.76 | -18.25 | -9.92 | -19.55 | Upgrade
|
| Capital Expenditures | -0.08 | -0.02 | -0.27 | -0.47 | -0.21 | Upgrade
|
| Investment in Securities | -46.83 | -0.28 | - | - | - | Upgrade
|
| Other Investing Activities | - | -0.22 | 0.3 | -0.36 | -0.29 | Upgrade
|
| Investing Cash Flow | -46.91 | -0.51 | 0.03 | -0.83 | -0.5 | Upgrade
|
| Long-Term Debt Issued | 2.11 | 5.02 | 12.06 | 15.28 | 6.96 | Upgrade
|
| Long-Term Debt Repaid | -6.25 | -3.36 | -1.8 | -0.59 | -0.81 | Upgrade
|
| Net Debt Issued (Repaid) | -4.15 | 1.67 | 10.26 | 14.69 | 6.15 | Upgrade
|
| Issuance of Common Stock | 1.16 | 11.66 | - | 0.27 | 18.63 | Upgrade
|
| Other Financing Activities | -0.47 | - | 0.01 | - | -1.2 | Upgrade
|
| Financing Cash Flow | -3.46 | 13.32 | 10.27 | 14.96 | 23.58 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | -0 | - | - | - | Upgrade
|
| Net Cash Flow | -1.93 | -6.95 | -7.96 | 4.21 | 3.53 | Upgrade
|
| Free Cash Flow | 48.36 | -19.78 | -18.53 | -10.39 | -19.76 | Upgrade
|
| Free Cash Flow Margin | 57.97% | -888.19% | -101.22% | -39.50% | -189.65% | Upgrade
|
| Free Cash Flow Per Share | 1.89 | -1.01 | -1.00 | -0.57 | -1.27 | Upgrade
|
| Cash Interest Paid | 0.47 | - | - | - | - | Upgrade
|
| Cash Income Tax Paid | - | - | - | - | 0.05 | Upgrade
|
| Levered Free Cash Flow | 33.19 | -11.18 | -9.07 | -4.21 | -12.47 | Upgrade
|
| Unlevered Free Cash Flow | 35.17 | -9.8 | -8.21 | -3.69 | -12.3 | Upgrade
|
| Change in Working Capital | -0.64 | -1.05 | -3.38 | 0.69 | -3.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.